Leerink Partnrs Decreases Earnings Estimates for Beigene

Beigene, Ltd. (NASDAQ:ONC) – Research analysts at Leerink Partnrs cut their FY2026 earnings estimates for shares of Beigene in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn $7.06 per share for the year, down from their prior estimate of $7.33. The consensus estimate for Beigene’s current full-year earnings is ($5.82) per share.

A number of other analysts also recently commented on the stock. Macquarie boosted their target price on shares of Beigene from $259.00 to $313.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Bank of America upgraded shares of Beigene from a “neutral” rating to a “buy” rating and boosted their target price for the stock from $207.00 to $320.00 in a report on Monday.

Beigene Trading Up 4.8 %

NASDAQ ONC opened at $257.31 on Monday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. Beigene has a 12 month low of $126.97 and a 12 month high of $287.88. The company has a market capitalization of $25.18 billion, a P/E ratio of -31.23, a price-to-earnings-growth ratio of 7.73 and a beta of 0.63.

Beigene (NASDAQ:ONC) last issued its quarterly earnings results on Thursday, February 27th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.55). The company had revenue of $1.13 billion during the quarter, compared to analyst estimates of $1.09 billion. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%.

Insider Buying and Selling

In other news, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $258.04, for a total transaction of $310,164.08. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Bros. Advisors Lp Baker sold 732,827 shares of the business’s stock in a transaction that occurred on Friday, February 28th. The shares were sold at an average price of $260.00, for a total transaction of $190,535,020.00. Following the sale, the director now owns 730,642 shares in the company, valued at $189,966,920. This represents a 50.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 790,950 shares of company stock worth $204,616,547 in the last ninety days. 7.43% of the stock is currently owned by corporate insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.